Importance of Serum p53 Antibodies during Follow-Up after Treatment of Invasive Bladder Tumors

Abstract

Introduction: To investigate the prognostic importance of the changes in serum p53 antibody titrations during follow-up of patients who had anti-p53 antibody-positive invasive bladder tumors with transitional epithelial cells. Materials and Methods: The study group consisted of 23 clinically T3≤, N0, M0 patients with positive serum anti-p53 antibodies before treatment. 23 cases with negative serum anti-p53 antibodies who were comparable in age, comorbidity and stage with the study group were selected as a control group. The cases whose serum anti-p53 titrations decreased to normal levels after treatment were compared for metastases, death rates and survival with cases who remained serum anti-p53-positive and those who were serum p53 antibody-negative before treatment. Serum anti-p53 antibody titration was determined by ELISA. Results: While serum anti-p53 antibody titrations became negative in 8 (35%) of the 23 seropositive patients, it did not change in 15 patients (65%). There was a correlation between the maintenance of seropositivity, local progression/metastasis and death (p < 0.05). Survival was found to be better in cases who were seronegative after treatment compared with cases who remained positive and also those who were seronegative before treatment (p < 0.05). Conclusion: The normalization of serum anti-p53 antibody positivity after treatment of invasive bladder tumors seems to be a good and reliable prognostic indicator.

Serum p53 antibodies as a prognostic indicator in oral squamous cell carcinoma

“…Several studies have reported that patients negative for p53 Abs at the time of diagnosis did not become positive during follow-up. 25,26 Gumus et al 27 recently found no change in serum p53 Abs during the follow-up of 23 patients with invasive bladder tumors who were negative for p53 Abs before treatment, regardless of outcome, and they suggested that it was suffi cient to monitor the status of serum p53 Abs only in patients positive for serum p53 Abs at the time of diagnosis. We agree with this conclusion.…”